Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin

Science Translational Medicine

Volumn 6, Issue 261, 2014, Pages

  Laughney, Ashley M ^a   Kim, Eunha ^a   Sprachman, Melissa M ^a   Miller, Miles A ^a   Kohler, Rainer H ^a   Yang, Katy S ^a   Orth, James D ^b,c   Mitchison, Timothy J ^b   Weissleder, Ralph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERIBULIN; ERIBULIN BORON DIPYRROMETHENE FLUOROPHORE; FLUORESCENT DYE; HYBRID PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; N [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; 4-OXO-4H-CHROMENE-2-CARBOXYLIC ACID (2-(2-(4-(2-(6,7-DIMETHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHYL)-PHENYL)-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL)AMIDE; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BENZOPYRAN DERIVATIVE; DRUG CARRIER; FURAN DERIVATIVE; ISOQUINOLINE DERIVATIVE; KETONE; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; TETRAZOLE DERIVATIVE; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CELL SUBPOPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; ENCAPSULATION; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SINGLE CELL ANALYSIS; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TUMOR MODEL; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CHEMISTRY; CONFOCAL MICROSCOPY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; GENETICS; MEDICINAL CHEMISTRY; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; FURANS; HUMANS; ISOQUINOLINES; KETONES; MICE, NUDE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NEOPLASMS; P-GLYCOPROTEINS; RECOMBINANT FUSION PROTEINS; TETRAZOLES; TRANSFECTION; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908876318     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009318     Document Type: Article

References (41)

1. S. Arao, H. Suwa, M. Mandai, H. Tashiro, K. Miyazaki, H. Okamura, H. Nomura, H. Hiai, M. Fukumoto, Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res. 54, 1355-1359 (1994).
2. R. J. Arceci, Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81, 2215-2222 (1993).
3. D. R. Bell, J. H. Gerlach, N. Kartner, R. N. Buick, V. Ling, Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J. Clin. Oncol. 3, 311-315 (1985).
4. W. S. Dalton, T. M. Grogan, J. A. Rybski, R. J. Scheper, L. Richter, J. Kailey, H. J. Broxterman, H. M. Pinedo, S. E. Salmon, Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood 73, 747-752 (1989).
5. R. Pirker, J. Wallner, K. Geissler, W. Linkesch, O. A. Haas, P. Bettelheim, M. Hopfner, R. Scherrer, P. Valent, L. Havelec, H. Ludwig, K. Lechner, MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 83, 708-712 (1991).
6. H. Sato, H. Preisler, R. Day, A. Raza, R. Larson, G. Browman, J. Goldberg, R. Vogler, H. Grunwald, A. Gottlieb, J. Bennett, M. Gottesman, I. Pastan, MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br. J. Haematol. 75, 340-345 (1990).
7. U. S. Food and Drug Administration. FDA approves new treatment option for late-stage breast cancer (15 November 2010).
8. J. Cortes, J. O'Shaughnessy, D. Loesch, J. L. Blum, L. T. Vahdat, K. Petrakova, P. Chollet, A. Manikas, V. Diéras, T. Delozier, V. Vladimirov, F. Cardoso, H. Koh, P. Bougnoux, C. E. Dutcus, S. Seegobin, D. Mir, N. Meneses, J. Wanders, C. Twelves; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 377, 914-923 (2011).
9. Kaufman, P. Study finds greater potential benefit in overall survival for eribulin compared with capecitabine (12 June 2013).
10. S. Saji, Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane. BioDrugs 27, 469-478 (2013).
11. M. J. Towle, K. A. Salvato, J. Budrow, B. F. Wels, G. Kuznetsov, K. K. Aalfs, S. Welsh, W. Zheng, B. M. Seletsky, M. H. Palme, G. J. Habgood, L. A. Singer, L. V. Dipietro, Y. Wang, J. J. Chen, D. A. Quincy, A. Davis, K. Yoshimatsu, Y. Kishi, M. J. Yu, B. A. Littlefield, In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013-1021 (2001).
12. Z. Binkhathlan, A. Lavasanifar, P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr. Cancer Drug Targets 13, 326-346 (2013).
13. R. Krishna, G. De Jong, L. D. Mayer, Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. Anticancer Res. 17, 3329-3334 (1997).
14. Y. J. Cha, H. Lee, N. Gu, T. E. Kim, K. S. Lim, S. H. Yoon, J. Y. Chung, I. J. Jang, S. G. Shin, K. S. Yu, J. Y. Cho, Sustained increase in the oral bioavailability of loperamide after a single oral dose of HM30181, a P-glycoprotein inhibitor, in healthy male participants. Basic Clin. Pharmacol. Toxicol. (2013).
15. T. E. Kim, N. Gu, S. H. Yoon, J. Y. Cho, K. M. Park, S. G. Shin, I. J. Jang, K. S. Yu, Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: Single- and multiple-dose randomized, placebo-controlled studies. Clin. Ther. 34, 482-494 (2012).
16. J. O. Kwak, S. H. Lee, G. S. Lee, M. S. Kim, Y. G. Ahn, J. H. Lee, S. W. Kim, K. H. Kim, M. G. Lee, Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur. J. Pharmacol. 627, 92-98 (2010).
17. L. Pusztai, P. Wagner, N. Ibrahim, E. Rivera, R. Theriault, D. Booser, F. W. Symmans, F. Wong, G. Blumenschein, D. R. Fleming, R. Rouzier, G. Boniface, G. N. Hortobagyi, Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104, 682-691 (2005).
18. M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, L. Wilson, The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086-1095 (2005).
19. T. Okouneva, O. Azarenko, L. Wilson, B. A. Littlefield, M. A. Jordan, Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 7, 2003-2011 (2008).
20. S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad, S. J. Lippard, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 105, 17356-17361 (2008).
21. N. Kamaly, G. Fredman, M. Subramanian, S. Gadde, A. Pesic, L. Cheung, Z. A. Fayad, R. Langer, I. Tabas, O. C. Farokhzad, Development and in vivo efficacy of targeted polymeric inflammationresolving nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 110, 6506-6511 (2013).
22. L. A. Diaz Jr., R. T. Williams, J. Wu, I. Kinde, J. R. Hecht, J. Berlin, B. Allen, I. Bozic, J. G. Reiter, M. A. Nowak, K. W. Kinzler, K. S. Oliner, B. Vogelstein, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
23. J. Chen, Z. Ding, Y. Peng, F. Pan, J. Li, L. Zou, Y. Zhang, H. Liang, HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLOS One 9, e98882 (2014).
24. K. M. Comerford, T. J. Wallace, J. Karhausen, N. A. Louis, M. C. Montalto, S. P. Colgan, Hypoxiainducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62, 3387-3394 (2002).
25. Z. Ding, L. Yang, X. Xie, F. Xie, F. Pan, J. Li, J. He, H. Liang, Expression and significance of hypoxia-inducible factor-1 α and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J. Cancer Res. Clin. Oncol. 136, 1697-1707 (2010).
26. L. Nardinocchi, R. Puca, A. Sacchi, G. D'Orazi, Inhibition of HIF-1α activity by homeodomaininteracting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol. Cancer 8, 1 (2009).
27. X. Song, X. Liu, W. Chi, Y. Liu, L. Wei, X. Wang, J. Yu, Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene. Cancer Chemother. Pharmacol. 58, 776-784 (2006).
28. J. Xie, D. W. Li, X. W. Chen, F. Wang, P. Dong, Expression and significance of hypoxiainducible factor-1a and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. Oncol. Lett. 6, 232-238 (2013).
29. H. Zhu, X. P. Chen, S. F. Luo, J. Guan, W. G. Zhang, B. X. Zhang, Involvement of hypoxiainducible factor-1-α in multidrug resistance induced by hypoxia in HepG2 cells. J. Exp. Clin. Cancer Res. 24, 565-574 (2005).
30. M. Raderer, W. Scheithauer, Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72, 3553-3563 (1993).
31. R. Krishna, L. D. Mayer, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283 (2000).
32. N. Kamaly, Z. Xiao, P. M. Valencia, A. F. Radovic-Moreno, O. C. Farokhzad, Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem. Soc. Rev. 41, 2971-3010 (2012).
33. Y. Yan, G. K. Such, A. P. Johnston, J. P. Best, F. Caruso, Engineering particles for therapeutic delivery: Prospects and challenges. ACS Nano. 6, 3663-3669 (2012).
34. P. Yan, X. Zhou, M. Shah, S. T. Wong, Automatic segmentation of high-throughput RNAi fluorescent cellular images. IEEE Trans. Inf. Technol. Biomed. 12, 109-117 (2008).
35. G. M. Thurber, K. S. Yang, T. Reiner, R. H. Kohler, P. Sorger, T. Mitchison, R. Weissleder, Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat. Commun. 4, 1504 (2013).
36. I. Pastan, M. M. Gottesman, K. Ueda, E. Lovelace, A. V. Rutherford, M. C. Willingham, A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. U. S. A. 85, 4486-4490 (1988).
37. T. Reiner, J. Lacy, E. J. Keliher, K. S. Yang, A. Ullal, R. H. Kohler, C. Vinegoni, R. Weissleder, Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 14, 169-177 (2012).
38. E. Hopper, M. G. Belinsky, H. Zeng, A. Tosolini, J. R. Testa, G. D. Kruh, Analysis of the structure and expression pattern of MRP7(ABCC10), a new member of the MRP subfamily. Cancer Lett. 162, 181-191 (2001).
39. M. Vendrell, G. G. Krishna, K. K. Ghosh, D. Zhai, J. S. Lee, Q. Zhu, Y. H. Yau, S. G. Shochat, H. Kim, J. Chung, Y. T. Chang, Solid-phase synthesis of BODIPY dyes and development of an immunoglobulin fluorescent sensor. Chem. Commun. 47, 8424-8426 (2011).
40. J. Condeelis, R. Weissleder, In vivo imaging in cancer. Cold Spring Harb. Perspect. Biol. 2, a003848 (2010).
41. M. J. Pittet, R. Weissleder, Intravital imaging. Cell 147, 983-991 (2011).